Historical record - last NADAC effective date: 1/14/2016
Product Information
ARANESP 100 MCG/0.5 ML SYRINGE is a brand product labeled by Amgen Inc., priced at $1427.5279 per ML under NDC 55513002504. Its NADAC has been published 164 times since Nov 28, 2013.
Strength
100 ug/.5mL
Manufacturer
Amgen Inc.NDC
55513002504
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
1/14/2016
Active Ingredients
DARBEPOETIN ALFAApproval Type
Biologic (BLA)
FDA Application
BLA103951On Market Since
8/14/2006
Pharmacological Classes
Price Statistics
The NADAC for ARANESP 100 MCG/0.5 ML SYRINGE has been published 164 times since Nov 28, 2013, and over the history we have for it it has risen 19.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1427.5279 per ML |
|---|---|
| All-time high | $1427.5279 (Jan 11, 2017) |
| All-time low | $1193.0020 (Nov 28, 2013) |
| Median price | $1359.2914 |
| Average price | $1339.9971 |
| Largest weekly change | +5.0% (Jan 20, 2016) |
| Weeks tracked | 164 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+19.7%
Last surveyed Jan 11, 2017 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the darbepoetin alfa market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amgen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
darbepoetin alfa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Erythropoiesis-stimulating Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ARANESP 100 MCG/0.5 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for ARANESP 100 MCG/0.5 ML SYRINGE, manufactured by Amgen Inc., is $1427.5279 per ML (NDC 55513002504), effective Jan 11, 2017.
How has the price of ARANESP 100 MCG/0.5 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for ARANESP 100 MCG/0.5 ML SYRINGE has risen 19.7%. It has been tracked across 164 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ARANESP 100 MCG/0.5 ML SYRINGE?
Since Nov 28, 2013, the NADAC for ARANESP 100 MCG/0.5 ML SYRINGE has ranged from a low of $1193.0020 (Nov 28, 2013) to a high of $1427.5279 (Jan 11, 2017), with a median of $1359.2914 per ML.
Are there cheaper alternatives to ARANESP 100 MCG/0.5 ML SYRINGE?
No other NADAC-published product currently shares the active ingredient and strength of ARANESP 100 MCG/0.5 ML SYRINGE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ARANESP 100 MCG/0.5 ML SYRINGE?
ARANESP 100 MCG/0.5 ML SYRINGE (NDC 55513002504) is labeled by Amgen Inc., and CMS classifies it as a brand product.